Publications
Detailed Information
A randomized phase II study of acyclovir for the prevention of chemotherapy-induced oral mucositis in patients undergoing autologous hematopoietic stem cell transplantation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Junshik | - |
dc.contributor.author | Park, Hee-Kyung | - |
dc.contributor.author | Chang, Sung-Ho | - |
dc.contributor.author | Byun, Ja Min | - |
dc.contributor.author | Shin, Dong-Yeop | - |
dc.contributor.author | Koh, Youngil | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.contributor.author | Choi, Youngnim | - |
dc.contributor.author | Kim, Inho | - |
dc.date.accessioned | 2023-12-18T00:54:22Z | - |
dc.date.available | 2023-12-18T09:54:58Z | - |
dc.date.issued | 2023-12-15 | - |
dc.identifier.citation | BMC Oral Health, Vol.23(1):1008 | ko_KR |
dc.identifier.issn | 1472-6831 | - |
dc.identifier.uri | https://hdl.handle.net/10371/198711 | - |
dc.description.abstract | Objectives
To prove our hypothesis that acyclovir prophylaxis in autologous hematopoietic stem cell transplantation (AHSCT) recipients with hematologic malignancies (HM) reduces the incidence of chemotherapy-induced oral mucositis (CIOM) by inhibiting the intraoral HSV reactivation during the neutropenic period, we conducted a randomized phase II study of acyclovir for the prevention of CIOM in adult HSV sero-positive AHSCT recipients. Methods Patients were randomized to either the study group (acyclovir 400 mg PO bid until neutrophil engraftment) or the control group (no prophylaxis) and received AHSCT. Oral examination and sampling for HSV were performed at three timepoints of AHSCT. Results In 54 patients who were randomized (for intention-to-analysis), the incidence of CIOM was 16.0% (4/25 patients) and 58.6% (17/29 patients) in the study group and the control group, respectively (P = 0.001). In 49 patients who completed the study (for per-protocol analysis), the incidence of CIOM was 13.0% (3/23 patients) and 61.5% (16/26 patients) in the study group and the control group, respectively (P = 0.001). In addition, HSV-1 PCR positivity in the study group was significantly lower than that the control group (4.3% vs. 46.2%, P = 0.001). A strong association between the HSV-1 reactivation status and CIOM was reconfirmed. Conclusions Prophylactic use of oral acyclovir effectively reduced the incidence of CIOM in patients with HM who were undergoing AHSCT. | ko_KR |
dc.description.sponsorship | This research was supported by the Mid-Career Researcher Program of the National Research Foundation funded by the Ministry of Science & ICT, Republic of Korea (2017R1A2B4002176) to HKP and by the National Research Foundation of Korea (Daejun, Korea) through grants 2018R1A5A2024418 and 2020R1A2C1100163 to YC | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BMC | ko_KR |
dc.subject | Oral mucositis | - |
dc.subject | Herpes simplex virus | - |
dc.subject | Autologous stem cell transplantation | - |
dc.subject | Acyclovir | - |
dc.subject | Chemotherapy | - |
dc.title | A randomized phase II study of acyclovir for the prevention of chemotherapy-induced oral mucositis in patients undergoing autologous hematopoietic stem cell transplantation | ko_KR |
dc.type | Article | ko_KR |
dc.identifier.doi | 10.1186/s12903-023-03623-6 | ko_KR |
dc.citation.journaltitle | BMC Oral Health | ko_KR |
dc.language.rfc3066 | en | - |
dc.rights.holder | The Author(s) | - |
dc.date.updated | 2023-12-17T04:08:47Z | - |
dc.citation.endpage | 7 | ko_KR |
dc.citation.number | 1 | ko_KR |
dc.citation.startpage | 1 | ko_KR |
dc.citation.volume | 23 | ko_KR |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.